What is Epsilogen?
Epsilogen operates at the vanguard of biopharmaceutical innovation, specializing in the development of pan-isotype antibody therapeutics. By focusing on the unique properties of immunoglobulin IgE, IgA, and IgG, the company is pioneering a new class of cancer treatments designed to optimize immune system engagement. Its lead candidate, MOv18 IgE, represents a significant breakthrough as the first therapeutic IgE antibody to enter clinical trials, specifically targeting folate receptors in patients suffering from platinum-resistant ovarian cancer. By systematically matching antibody isotypes to specific tumor microenvironments, Epsilogen is effectively bridging the gap between academic research and scalable clinical application, positioning itself as a critical player in the precision medicine landscape.
How much funding has Epsilogen raised?
Epsilogen has raised a total of $67.8M across 3 funding rounds:
Series A
$6.3M
Other Financing Round
$3.9M
Series B
$57.6M
Series A (2017): $6.3M with participation from UCL Technology Fund, Epidarex Capital, and Alsa Holdings
Other Financing Round (2020): $3.9M led by Epidarex Capital, UCL Technology Fund, and Alsa Holdings
Series B (2024): $57.6M supported by Caribou Property Management, Novartis Venture Fund, British Patient Capital, 3B Future Health Fund, ALSA Ventures, Epidarex Capital, and Schroders Capital
Key Investors in Epsilogen
Novartis Venture Fund
A prominent life science investment arm focused on biotechnology and biopharmaceutical therapeutics that address critical unmet patient needs.
Epidarex Capital
A transatlantic venture capital firm specializing in building breakthrough life science companies and precision medicine startups in emerging hubs.
British Patient Capital
A government-backed investment entity dedicated to providing long-term equity finance to support the growth and scaling of innovative UK-based businesses.
What's next for Epsilogen?
With this major enterprise-level funding, Epsilogen is well-positioned to accelerate its clinical development pipeline and expand its research capabilities. The strategic focus will likely shift toward scaling the manufacturing processes for its lead candidates and broadening the scope of its clinical trials to include a wider array of solid tumors. As the company transitions from early-stage development to a more mature clinical phase, the focus will remain on demonstrating the efficacy of its pan-isotype approach in human subjects. This capital provides the necessary runway to navigate the complex regulatory environment and potentially secure future partnerships with larger pharmaceutical entities, ultimately aiming to bring transformative, isotype-specific therapies to market for patients with high unmet medical needs.
See full Epsilogen company page
